The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
- 15 May 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (10), 3176-3187
- https://doi.org/10.1158/1078-0432.ccr-18-1597
Abstract
Purpose: Knowledge about the mechanism of action (MoA) of monoclonal antibodies (mAbs) is required to understand which multiple myeloma (MM) patients benefit the most from a given mAb, alone or in combination therapy. While there is considerable research about daratumumab, knowledge about other anti-CD38 mAbs remains scarce. Experimental Design: We performed a comprehensive analysis about the MoA of isatuximab. Results: Isatuximab induces internalization of CD38 but not significant release from MM cell' surface. Additionally, we uncovered an association between levels of CD38 expression and different MoA: i) isatuximab was able to induce direct apoptosis on MM cells with very high CD38 but not on MM cells with CD38 levels closer to those in MM patients; ii) isatuximab sensitized CD38hi MM cells to bortezomib plus dexamethasone in the presence of stroma; iii) antibody-dependent cellular cytotoxicity (ADCC) was triggered by CD38lo and CD38hi tumor PCs; iv) antibody-dependent cellular phagocytosis (ADCP) was triggered only by CD38hi MM cells, whereas; v) complement-dependent cytotoxicity could be triggered in less than half of the patient samples (those with elevated levels of CD38). Furthermore, we showed that isatuximab depletes CD38hi B-lymphocyte precursors and NK-lymphocytes ex vivo, the latter through activation followed by exhaustion and eventually phagocytosis. Conclusions: This study provides a framework to understand response determinants in patients treated with isatuximab based on the number of MoA triggered by CD38 levels of expression, and for the design of effective combinations aimed at capitalizing disrupted tumor-stroma-cell protection, augmenting NK-lymphocyte mediated ADCC, or facilitating ADCP in CD38lo MM patients.Keywords
Other Versions
Funding Information
- del Instituto de Salud Carlos III (CB16/12/00369, CB16/12/00489, CB16/12/00443)
- Cooperative Research Thematic Network (RD12/0036/0058, RD12/0036/0068)
- FIS (PI17/01243, PI17/00411)
This publication has 44 references indexed in Scilit:
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibClinical Cancer Research, 2015
- Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomideHaematologica, 2014
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic MalignanciesClinical Cancer Research, 2014
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodiesBlood, 2011
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activityNature Medicine, 2010
- Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cellsHaematologica, 2010
- Human peripheral blood B‐cell compartments: A crossroad in B‐cell trafficCytometry Part B: Clinical Cytometry, 2010
- CD38 at the junction between prognostic marker and therapeutic targetTrends in Molecular Medicine, 2008